Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates

Damian J. Green, John M. Pagel, Eneida Nemecek, Yukang Lin, Aimee Kenoyer, Anastasia Pantelias, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Joseph G. Rajendran, Ajay K. Gopal, Steven I. Park, Oliver W. Press

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Pretargeted radioimmunotherapy (PRIT) is designed to enhance the directed delivery of radionuclides to malignant cells. Through a series of studies in 19 nonhuman primates (Macaca fascicularis), the potential therapeutic advantage of anti-CD45 PRIT was evaluated. Anti-CD45 PRIT demonstrated a significant improvement in target-to-normal organ ratios of absorbed radiation compared with directly radiolabeled bivalent antibody (conventional radioimmunotherapy [RIT]). Radio-DOTA-biotin administered 48 hours after anti-CD45 streptavidin fusion protein (FP) [BC8 (scFv)4SA] produced markedly lower concentrations of radiation in nontarget tissues compared with conventional RIT. PRIT generated superior target:normal organ ratios in the blood, lung, and liver (10.3:1, 18.9:1, and 9.9:1, respectively) compared with the conventional RIT controls (2.6:1, 6.4:1, and 2.9:1, respectively). The FP demonstrated superior retention in target tissues relative to comparable directly radiolabeled bivalent anti-CD45 RIT. The time point of administration of the second step radiolabeled ligand (radio-DOTA-biotin) significantly impacted the biodistribution of radioactivity in target tissues. Rapid clearance of the FP from the circulation rendered unnecessary the addition of a synthetic clearing agent in this model. These results support proceeding to anti-CD45 PRIT clinical trials for patients with both leukemia and lymphoma.

Original languageEnglish (US)
Pages (from-to)1226-1335
Number of pages110
JournalBlood
Volume114
Issue number6
DOIs
StatePublished - 2009

Fingerprint

Radioimmunotherapy
Primates
Fusion reactions
Radiation
Tissue
Proteins
Streptavidin
Radioactivity
Radioisotopes
Liver
Blood
Ligands
Radio
Antibodies
Macaca fascicularis
DOTA-biotin
Lymphoma
Leukemia
Clinical Trials
Lung

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. / Green, Damian J.; Pagel, John M.; Nemecek, Eneida; Lin, Yukang; Kenoyer, Aimee; Pantelias, Anastasia; Hamlin, Donald K.; Wilbur, D. Scott; Fisher, Darrell R.; Rajendran, Joseph G.; Gopal, Ajay K.; Park, Steven I.; Press, Oliver W.

In: Blood, Vol. 114, No. 6, 2009, p. 1226-1335.

Research output: Contribution to journalArticle

Green, DJ, Pagel, JM, Nemecek, E, Lin, Y, Kenoyer, A, Pantelias, A, Hamlin, DK, Wilbur, DS, Fisher, DR, Rajendran, JG, Gopal, AK, Park, SI & Press, OW 2009, 'Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates', Blood, vol. 114, no. 6, pp. 1226-1335. https://doi.org/10.1182/blood-2009-03-210344
Green, Damian J. ; Pagel, John M. ; Nemecek, Eneida ; Lin, Yukang ; Kenoyer, Aimee ; Pantelias, Anastasia ; Hamlin, Donald K. ; Wilbur, D. Scott ; Fisher, Darrell R. ; Rajendran, Joseph G. ; Gopal, Ajay K. ; Park, Steven I. ; Press, Oliver W. / Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. In: Blood. 2009 ; Vol. 114, No. 6. pp. 1226-1335.
@article{b973e245eddf46e3a0e9926ee72897d0,
title = "Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates",
abstract = "Pretargeted radioimmunotherapy (PRIT) is designed to enhance the directed delivery of radionuclides to malignant cells. Through a series of studies in 19 nonhuman primates (Macaca fascicularis), the potential therapeutic advantage of anti-CD45 PRIT was evaluated. Anti-CD45 PRIT demonstrated a significant improvement in target-to-normal organ ratios of absorbed radiation compared with directly radiolabeled bivalent antibody (conventional radioimmunotherapy [RIT]). Radio-DOTA-biotin administered 48 hours after anti-CD45 streptavidin fusion protein (FP) [BC8 (scFv)4SA] produced markedly lower concentrations of radiation in nontarget tissues compared with conventional RIT. PRIT generated superior target:normal organ ratios in the blood, lung, and liver (10.3:1, 18.9:1, and 9.9:1, respectively) compared with the conventional RIT controls (2.6:1, 6.4:1, and 2.9:1, respectively). The FP demonstrated superior retention in target tissues relative to comparable directly radiolabeled bivalent anti-CD45 RIT. The time point of administration of the second step radiolabeled ligand (radio-DOTA-biotin) significantly impacted the biodistribution of radioactivity in target tissues. Rapid clearance of the FP from the circulation rendered unnecessary the addition of a synthetic clearing agent in this model. These results support proceeding to anti-CD45 PRIT clinical trials for patients with both leukemia and lymphoma.",
author = "Green, {Damian J.} and Pagel, {John M.} and Eneida Nemecek and Yukang Lin and Aimee Kenoyer and Anastasia Pantelias and Hamlin, {Donald K.} and Wilbur, {D. Scott} and Fisher, {Darrell R.} and Rajendran, {Joseph G.} and Gopal, {Ajay K.} and Park, {Steven I.} and Press, {Oliver W.}",
year = "2009",
doi = "10.1182/blood-2009-03-210344",
language = "English (US)",
volume = "114",
pages = "1226--1335",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates

AU - Green, Damian J.

AU - Pagel, John M.

AU - Nemecek, Eneida

AU - Lin, Yukang

AU - Kenoyer, Aimee

AU - Pantelias, Anastasia

AU - Hamlin, Donald K.

AU - Wilbur, D. Scott

AU - Fisher, Darrell R.

AU - Rajendran, Joseph G.

AU - Gopal, Ajay K.

AU - Park, Steven I.

AU - Press, Oliver W.

PY - 2009

Y1 - 2009

N2 - Pretargeted radioimmunotherapy (PRIT) is designed to enhance the directed delivery of radionuclides to malignant cells. Through a series of studies in 19 nonhuman primates (Macaca fascicularis), the potential therapeutic advantage of anti-CD45 PRIT was evaluated. Anti-CD45 PRIT demonstrated a significant improvement in target-to-normal organ ratios of absorbed radiation compared with directly radiolabeled bivalent antibody (conventional radioimmunotherapy [RIT]). Radio-DOTA-biotin administered 48 hours after anti-CD45 streptavidin fusion protein (FP) [BC8 (scFv)4SA] produced markedly lower concentrations of radiation in nontarget tissues compared with conventional RIT. PRIT generated superior target:normal organ ratios in the blood, lung, and liver (10.3:1, 18.9:1, and 9.9:1, respectively) compared with the conventional RIT controls (2.6:1, 6.4:1, and 2.9:1, respectively). The FP demonstrated superior retention in target tissues relative to comparable directly radiolabeled bivalent anti-CD45 RIT. The time point of administration of the second step radiolabeled ligand (radio-DOTA-biotin) significantly impacted the biodistribution of radioactivity in target tissues. Rapid clearance of the FP from the circulation rendered unnecessary the addition of a synthetic clearing agent in this model. These results support proceeding to anti-CD45 PRIT clinical trials for patients with both leukemia and lymphoma.

AB - Pretargeted radioimmunotherapy (PRIT) is designed to enhance the directed delivery of radionuclides to malignant cells. Through a series of studies in 19 nonhuman primates (Macaca fascicularis), the potential therapeutic advantage of anti-CD45 PRIT was evaluated. Anti-CD45 PRIT demonstrated a significant improvement in target-to-normal organ ratios of absorbed radiation compared with directly radiolabeled bivalent antibody (conventional radioimmunotherapy [RIT]). Radio-DOTA-biotin administered 48 hours after anti-CD45 streptavidin fusion protein (FP) [BC8 (scFv)4SA] produced markedly lower concentrations of radiation in nontarget tissues compared with conventional RIT. PRIT generated superior target:normal organ ratios in the blood, lung, and liver (10.3:1, 18.9:1, and 9.9:1, respectively) compared with the conventional RIT controls (2.6:1, 6.4:1, and 2.9:1, respectively). The FP demonstrated superior retention in target tissues relative to comparable directly radiolabeled bivalent anti-CD45 RIT. The time point of administration of the second step radiolabeled ligand (radio-DOTA-biotin) significantly impacted the biodistribution of radioactivity in target tissues. Rapid clearance of the FP from the circulation rendered unnecessary the addition of a synthetic clearing agent in this model. These results support proceeding to anti-CD45 PRIT clinical trials for patients with both leukemia and lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=69849102685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69849102685&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-03-210344

DO - 10.1182/blood-2009-03-210344

M3 - Article

C2 - 19515724

AN - SCOPUS:69849102685

VL - 114

SP - 1226

EP - 1335

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -